Seahorse Bioscience Inc. wrapped up its latest funding round — the North Billerica, Mass.-based company’s fourth — pulling in $5 million.
Investors included Commonwealth Capital Ventures, HLM Venture Partners, Rock Maple Ventures, Oxford Bioscience Partners and HLM Venture Partners, all Boston-area venture capital funds. Atlanta-based Life Sciences Partners, New York-based New Science Ventures and Healthcare Ventures of Princeton, N.J., also returned for the deal.
Seahorse is working to commercialize its XF Series line of instruments, designed to measure energy consumption at the cellular level. The technology has been used by researchers to better understand metabolic deficiencies common to many neurological diseases, as well as obesity, diabetes, cancer and cardiovascular disease.
The company said proceeds will fund an expansion of its global sales and marketing efforts and hiring more staff at its manufacturing facility in Chicopee, Mass. In addition to the XF series, Seahorse also offers workstations using disposable plastic cards containing cell-culture chambers that mimic conditions inside a bench-scale bioreactor, related consumables and custom lab equipment.
Privately held Seahorse does not disclose revenues.